Please enter a search term.

Your selected location: Rhede (Ems) (268...)

For an area outside of Lower Saxony and foreign languages, some menu items and functions are not available. Please go to the service page of the respective country.

View summaries of risk management plans (RMPs) for authorized medicinal products


The Risk Management Plan (RMP) is a mandatory part of the marketing authorization documents of a medicinal product and is updated throughout the entire life cycle of a medicinal product.

The published RMP Summary is part of the RMP and describes the safety profile of a medicinal product and lists the measures planned for further investigation and monitoring of the risks and for their prevention or minimization.

By publishing the RMP summaries, the Federal Institute for Drugs and Medical Devices (BfArM) informs you as a user, for example as a

  • patients
  • nursing staff
  • Doctors and physicians,
  • pharmacist or as a representative of the
  • representatives of the healthcare system.

The RMP summaries are published in German and English on the portal for drug information of the federal and state governments (online platform PharmNet.Bund). On its website, the BfArM publishes a monthly updated list of preparations for which an RMP summary has already been posted on PharmNet.Bund.

The RMP summaries supplement the summaries of the Public Assessment Reports (PAR) on medicinal products as well as the package leaflets and information for healthcare professionals, which are also publicly available on PharmNet.Bund.

You do not need to submit any documents.

There are no prerequisites.

There are no costs.

  • Open the online platform PharmNet.Bund.
  • Click on "Drug information system" and then on "Search".
  • Accept the declaration of consent.
  • After entering the active substance or trade name you are looking for, you will be taken to the documents of the RMP summary (German and English) under "Additional documents".

The BfArM publishes the RMP summaries promptly after authorization of the corresponding medicinal products. Priority for publication is given to new authorizations of original preparations. Thereafter, RMP summaries for generics (copycat products) are also considered for publication.

There is no deadline.

The publication of the RMPs is not an appealable decision.

Forms available: No

Written form required: No

Informal application possible: No

Personal appearance necessary: No

Online services available: Yes

There are no indications or special features.

The text was automatically translated based on the German content.

Federal Ministry of Health (BMG)

06.05.2022

Responsible authorities


Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
Address: Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn, Stadt
Remark: Head office Bonn
Timetable
Address: Waisenhausgasse 36-38a, 50676 Köln, Stadt
Remark: Head office Cologne
Timetable
Telephone: +49 228 99307-0
Fax: +49 228 99307-5207
www: Contact

Source: Serviceportal Niedersachsen (Portalverbund des Bundes und der Länder)